Full text is available at the source.
Abstract
Immune checkpoint inhibitors (ICI) have demonstrated potential in treating adult cancers but show limited success in pediatric patients.
- Objective tumor responses and prolonged survival have been observed with ICI in adult cancers.
- Clinical trials are ongoing to evaluate the effectiveness of ICI in pediatric malignancies.
- There are unique immunologic and clinical challenges associated with using ICI in children.
- Future strategies may include combining ICI with other immune-based therapies and conventional treatments.
Simplified